Viatris Inc. (VTRS)
| Market Cap | 18.52B +48.7% |
| Revenue (ttm) | 14.74B +4.4% |
| Net Income | -410.70M |
| EPS | -0.35 |
| Shares Out | 1.15B |
| PE Ratio | n/a |
| Forward PE | 6.35 |
| Dividend | $0.48 (2.98%) |
| Ex-Dividend Date | Aug 21, 2026 |
| Volume | 5,329,522 |
| Open | 16.07 |
| Previous Close | 16.25 |
| Day's Range | 16.04 - 16.26 |
| 52-Week Range | 9.43 - 18.39 |
| Beta | 0.89 |
| Analysts | Buy |
| Price Target | 18.50 (+14.76%) |
| Earnings Date | Aug 6, 2026 |
About VTRS
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CN... [Read more]
Financial Performance
In 2025, Viatris's revenue was $14.30 billion, a decrease of -2.98% compared to the previous year's $14.74 billion. Losses were -$3.51 billion, 454.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for VTRS stock is "Buy." The 12-month stock price target is $18.5, which is an increase of 14.76% from the latest price.
News
Viatris Earnings Call Transcript: Q2 2026
Q2 revenues grew 3.5% year-over-year to $3.8 billion, with strong performance in Greater China and North America driving a guidance raise for all key 2026 metrics. Pipeline progress, cost savings, and capital returns support long-term growth, despite supply and policy headwinds.
Viatris Slides: Q2 2026
Viatris has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Viatris Earnings release: Q2 2026
Viatris released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Viatris Quarterly report: Q2 2026
Viatris has published its Q2 2026 quarterly earnings report on August 6, 2026.
Viatris Reports Second-Quarter 2026 Financial Results
Delivers Total Revenues of $3.8 Billion, Representing 5% Reported Growth Compared to Second Quarter 2025 and a U.S. GAAP Net Loss of $119 Million Total Revenues Were Up 3.5% Operationally Compared to ...
Viatris Announces Quarterly Dividend
PITTSBURGH, Aug. 4, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on August 3, 2026, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and...
Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch
New Patch Will Provide Low-Dose Estrogen Combined Hormonal Contraceptive Option Approval Marks an Important Milestone in Viatris' Efforts to Advance Women's Health PITTSBURGH, July 29, 2026 /PRNewswir...
Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply
Trump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at encouraging U.S. manufacturing. But thin profit margins make tariffs harder to absorb than for brande...
Mylan to sell up to $363 million stake in India's Biocon, term sheet shows
Mylan Inc plans to sell up to 92 million shares in Indian drugmaker Biocon Ltd , worth up to 34.81 billion Indian rupees ($363 million), according to a term sheet seen by Reuters.
Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026
PITTSBURGH, July 1, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report second-quarter 2026 financial results on Thursday, August 6, 2026. Com...
Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy
VR-205 Met Primary Endpoint and Key Secondary Endpoints and Was Well Tolerated VR-205 Efficacy and Safety Profile in Japanese Patients Was Consistent with the Profile Observed in Global Studies Japan...
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain
FDA PDUFA Goal Date Set for Dec. 27, 2026 PITTSBURGH, May 18, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration ...
Viatris Transcript: Bank of America Global Healthcare Conference 2026
North America growth is driven by generics and complex launches, with cost savings and strong free cash flow supporting flexibility. Key pipeline launches in Japan and North America, including meloxicam and selatogrel, are expected to accelerate growth, diversify revenue, and extend exclusivity.
Viatris to Present at the Bank of America Securities 2026 Healthcare Conference
PITTSBURGH, May 7, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the Bank of America Securities 2026 Healthcare Confer...
Viatris beats quarterly estimates on China strength, branded drug sales
Viatris topped analysts' estimates for first-quarter revenue and profit on Thursday, buoyed by strength in its China business and strong demand for branded drugs.
Viatris Earnings Call Transcript: Q1 2026
Q1 2026 saw 3% revenue growth to $3.5B and 10% adjusted EBITDA growth, led by strong performance in Greater China and North America. Multiple product launches and regulatory milestones are expected in 2026, with reaffirmed guidance and a focus on operational efficiency and capital allocation.
Viatris Slides: Q1 2026
Viatris has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Viatris Earnings release: Q1 2026
Viatris released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Viatris Quarterly report: Q1 2026
Viatris has published its Q1 2026 quarterly earnings report on May 7, 2026.
Viatris Reports First-Quarter 2026 Financial Results
Delivers Total Revenues of $3.5 Billion, Representing 8% Reported Growth Compared to First Quarter 2025, and U.S. GAAP Net Earnings of $176 Million Total Revenues Were Up 3% Operationally Compared to ...
Viatris Announces Chief Financial Officer Transition
Theodora "Doretta" Mistras to Depart; Paul Campbell Named Interim CFO PITTSBURGH, May 4, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Theodora "D...
Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting
PITTSBURGH, May 1, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that six abstracts on its investigational low-dose estrogen combined hormonal contrace...
Viatris to Report First Quarter 2026 Financial Results on May 7, 2026
PITTSBURGH, April 13, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report first quarter 2026 financial results on Thursday, May 7, 2026. Compa...
Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
PITTSBURGH, April 10, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that four abstracts will be presented at the American Society of Cataract and Refra...
Viatris Proxy statement: Proxy filing
Viatris filed a proxy statement on April 2, 2026, providing details for shareholder voting and corporate governance matters.